Evaluation of doxepin hydrochloride (Sinequan).
D000284:Administration, Oral; D000367:Age Factors; D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy; D002090:Butyrophenones / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy; D003865:Major Depressive Disorder; D003990:Dibenzoxepins / Q000627:therapeutic use*; D004285:Dogs; D005239:Fear; D000882:Haplorhini; D006801:Humans; D051379:Mice; D011437:Propylamines / Q000627:therapeutic use*; D051381:Rats; D012893:Sleep Wake Disorders; D013997:Time Factors
D000928:Antidepressive Agents; D002090:Butyrophenones; D003990:Dibenzoxepins; D011437:Propylamines